SEPTInvestingStart Free

SNSE 8-K: SEC filing

Filed with the SEC on · accession 0001193125-26-452755

SNSE filed a 8-K (current report) with the SEC on Nov 9, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Summary of the filing

Faeth Therapeutics made available a corporate presentation discussing topline clinical data from its Phase 2 PIK-201 trial evaluating PIKTOR in patients with advanced endometrial cancer.

For details, click here →How to read a 8-K →

Key details

RegistrantFaeth Therapeutics, Inc.
General counsel and secretaryChristopher W. Gerry

✦ Ask GOAX AI about this filing — what it means for SNSE, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for SNSE?

Click here

Frequently asked questions

What did SNSE file with the SEC on Nov 9, 2026?

SNSE filed a 8-K (SEC filing). Faeth Therapeutics made available a corporate presentation discussing topline clinical data from its Phase 2 PIK-201 trial evaluating PIKTOR in patients with advanced endometrial cancer.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Other SNSE SEC filings

Get alerts when SNSE files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days
SNSE overviewSNSE analysisSNSE newsLatest SEC filings